About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GL ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

The Centers for Medicare and Medicaid Services draft regulation also would introduce Medicare and Medicaid coverage of ...

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can ...

Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said. Amgen ...